Healthcare Industry News:  sentinel lymph node 

Devices Oncology

 News Release - October 9, 2006

Neoprobe Introduces Bluetooth Wireless Probe

New Probe Debuts at American College of Surgeons Meeting

DUBLIN, Ohio--(HSMN NewsFeed)--Neoprobe Corporation (OTCBB:NEOP ), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it introduced a new gamma detection probe at the American College of Surgeons 92nd Annual Clinical Congress meeting in Chicago. The new probe uses Bluetooth® wireless technology to communicate gamma radiation counts to the Company's neo2000® control unit. The wireless probe eliminates cumbersome cables that can complicate the surgical field and provides the surgeon with operative field flexibility. The new probe is designed to be used with all existing models of the Company's neo2000 system (Models 2000, 2100 and 2200). The wireless probe will be available with either a straight or angled detection tip. The neo2000 line of gamma detection systems are widely used by cancer surgeons in a procedure called sentinel lymph node Biopsy (SLNB) or Intraoperative Lymphatic Mapping (ILM).

David Bupp, Neoprobe's President and CEO, said, "We are excited by this new addition to our neo2000 gamma detection product line. We believe the introduction of a family of wireless gamma detection probes will offer the surgeon all of the advantages of a cordless instrument using state of the art Bluetooth technology coupled with the already easy-to-use features of our existing neo2000 control unit. The new wireless probes, along with the family of gamma detection probes that will continue to be offered, will only improve our position as the market leader in gamma detection and thus our market prospects. Because the Bluetooth probe will be usable with our existing installed base of neo2000 system control units, we believe our current customers as well as those considering the purchase of a gamma detection system will be pleased. We expect the first commercial shipments of the probe will occur during the fourth quarter of 2006. The Bluetooth probes, coupled with our clinical development program for the lymphatic tissue tracing agent Lymphoseek®, demonstrate Neoprobe's commitment to assist physicians in providing state of the art treatment for cancer patients."

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000® line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix® line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan® CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions.

Bluetooth is a registered trademark of Bluetooth Sig, Inc.

Source: Neoprobe

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.